Treatment of dry age-related macular degeneration

Giuseppe Querques, Philip J. Rosenfeld, Edoardo Cavallero, Enrico Borrelli, Federico Corvi, Lea Querques, Francesco M. Bandello, Marco A. Zarbin

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment

Original languageEnglish (US)
Pages (from-to)107-115
Number of pages9
JournalOphthalmic Research
Issue number3
StatePublished - Nov 19 2014

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


  • Age-related macular degeneration
  • Drugs
  • Drusen
  • Geographic atrophy
  • Neurotrophic factors
  • Oxidative damage
  • Pathway
  • Stem cells
  • Treatment
  • Visual cycle


Dive into the research topics of 'Treatment of dry age-related macular degeneration'. Together they form a unique fingerprint.

Cite this